Sur 2026, nous estimons que la dynamique sera plus favorable aux majors européennes tant sur le RASK (croissance plus modérée des capacités et meilleure orientation du réseau long-courrier en particulier transatlantique), que sur le CASK hors carburant aidé par des effets de base positifs. Nous relevons notre opinion à Surperformance sur Air France-KLM et Lufthansa et dégradons Ryanair en Neutre et Wizz Air en Sous-performance.
For 2026, we think that the trend will be more favourable to the European legacy carriers in terms of both RASK (more modest growth in capacity and a more positive trend on the long-haul network, particularly transatlantic) and CASK excluding fuel, aided by positive base effects. We have upgraded Air France-KLM and Lufthansa to Outperform, downgraded Ryanair to Neutral and Wizz Air to Underperform. A more favourable trend expected in 2026 for legacy carriers
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
KDP and JDE Peet's have announced that Kodiak BidCo (the bid vehicle for KDP) is making a recommended public cash o?er for all issued and outstanding ordinary shares in the capital of JDE Peet's at a price of €31.85. We see limited catalysts for the share price and expect the bid to succeed given that regulatory and union approvals have been secured and the majority shareholders have made an irrevocable undertaking to tender their shares to Kodiak BidCo. Therefore, we increase our 12-month targe...
JDE Peet’s launches Nature Transition Plan to advance regenerative agriculture and deforestation-free coffee supply chains PRESS RELEASE Amsterdam, January 29, 2026 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today unveiled its Nature Transition Plan – ‘Grounded in Nature’ – a science-based roadmap to protect ecosystems, strengthen farmer resilience, and secure the long-term viability of coffee production. The publication of the plan makes JDE Peet’s the first food and beverage company in the world to launch a nature transition plan that is fully aligned wi...
A director at Amadeus It Group S.A. sold 30,000 shares at 61.446EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Keurig Dr Pepper Launches Offer for JDE Peet’s Shares BURLINGTON, Mass., FRISCO, Texas and AMSTERDAM, January 15, 2026 – This is a joint press release by Keurig Dr Pepper Inc., Kodiak BidCo B.V. and JDE Peet’s N.V. pursuant to the provisions of Article 10, paragraph 3 and Article 18, paragraph 3 of the Dutch Decree on public takeover bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the Offer (as defined below). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in JDE Peet’s N.V. Any offer will be mad...
Notre 29ième Forum vient de se dérouler (8 et 9 janvier) à Lyon. Il a réuni 222 sociétés. L’édition 2026 de ce Forum a accueilli près de 500 investisseurs, travaillant pour environ 200 institutions de 13 pays. Nous avons ainsi organisé l’équivalent de 5 300 investors meetings. Ce document synthétise nos feed-back concernant les émetteurs obligataires présents.
argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.